Patents Assigned to Elan Pharma International Ltd.
-
Publication number: 20040258758Abstract: The present invention is directed to nanoparticulate compositions comprising topiramate. The topiramate particles of the composition have an effective average particle size of less than about 2 microns.Type: ApplicationFiled: January 30, 2004Publication date: December 23, 2004Applicant: Elan Pharma International, Ltd.Inventors: Evan Gustow, Tuula Ryde, Eugene R. Cooper
-
Publication number: 20040251332Abstract: A small-scale or micro media-mill and a method of milling materials or products, especially pharmaceutical products, use a dispersion containing attrition milling media and the product to be milled. The milling media can be polymeric, formed of polystyrene or cross-linked polystyrene, having a nominal diameter of no greater than 500 microns. Other sizes include 200 microns and 50 microns and a mixture of these sizes. The mill has a relatively small vessel having an opening, an agitator, a coupling and a motor. The agitator can have a rotor and a shaft extending therefrom. The rotor can be cylindrical or have other configurations, and can have tapered end surfaces. The coupling can close the vessel opening, or attaching the coupling to the motor can close the opening. The coupling has an opening through which the rotor shaft extends into the motor. A sealing mechanism, such as a mechanical or lip seals the shaft while permitting the rotor shaft to rotate.Type: ApplicationFiled: April 28, 2004Publication date: December 16, 2004Applicant: Elan Pharma International Ltd.Inventors: Robert Gary Reed, David A. Czekai, Henry William Bosch, Niels-Peter Moesgaard Ryde
-
Publication number: 20040229038Abstract: The present invention is directed to nanoparticulate compositions comprising meloxicam. The meloxicam particles of the composition have an effective average particle size of less than about 2000 nm.Type: ApplicationFiled: February 24, 2004Publication date: November 18, 2004Applicant: Elan Pharma International Ltd.Inventors: Eugene R. Cooper, Tuula Ryde, John Pruitt, Laura Kline
-
Publication number: 20040208833Abstract: The present invention is directed to fluticasone compositions comprising fluticasone and at least one surface stabilizer. The fluticasone particles of the composition preferably have an effective average particle size of less than about 2000 nm.Type: ApplicationFiled: February 2, 2004Publication date: October 21, 2004Applicant: Elan Pharma International Ltd.Inventors: Douglas Hovey, Tuula Ryde, H. William Bosch
-
Publication number: 20040195413Abstract: A system for milling at least one material, e.g., a drug. The system includes a milling apparatus and at least one milling medium. The milling apparatus includes a chamber having a rotary milling head located in it. The milling head is rotated within the chamber by a magnetic drive system.Type: ApplicationFiled: April 27, 2004Publication date: October 7, 2004Applicant: Elan Pharma International Ltd.Inventors: Robert G. Reed, David Czekai
-
Publication number: 20040173696Abstract: The present invention is directed to a method of milling small quantities of one or more candidate compounds to reduce the particle size of at least one candidate compound to about 2 microns or less. The apparatus used for the milling process can be one or more multi-well plates, or any other suitable apparatus. The resultant products are dispersions of nanoparticulate candidate compounds. The method is particularly suited for increasing the effectiveness of high throughput screening (“HTS”).Type: ApplicationFiled: December 17, 2003Publication date: September 9, 2004Applicant: Elan Pharma International Ltd.Inventors: James Cunningham, Elaine Liversidge, Eugene R. Cooper, Gary G. Liversidge
-
Publication number: 20040156872Abstract: The present invention provides nanoparticulate nimesulide compositions. The compositions preferably comprise nimesulide and at least one surface stabilizer adsorbed on or associated with the surface of the nimesulide particles. The nanoparticulate nimesulide particles preferably have an effective average particle size of less than about 2000 nm. The invention also provides methods of making and using nanoparticulate nimesulide compositions.Type: ApplicationFiled: October 31, 2003Publication date: August 12, 2004Applicant: Elan Pharma International Ltd.Inventors: H. William Bosch, Christian F. Wertz
-
Publication number: 20040156895Abstract: Disclosed are solid dosage forms of active agents and pullulan. The solid dosage form has a friability of less than about 1%.Type: ApplicationFiled: November 12, 2003Publication date: August 12, 2004Applicant: Elan Pharma International Ltd.Inventors: John D. Pruitt, Douglas C. Hovey, Tuula A. Ryde, H. William Bosch, Robert W. Lee
-
Publication number: 20040141925Abstract: The invention is directed to nanoparticulate triamcinolone and/or triamcinolone derivative compositions. The triamcinolone or triamcinolone derivative particles of the composition have an effective average particle size of less than about 2 microns.Type: ApplicationFiled: October 31, 2003Publication date: July 22, 2004Applicant: Elan Pharma International Ltd.Inventors: H. William Bosch, Kevin D. Ostrander, Eugene R. Cooper
-
Publication number: 20040115134Abstract: The present invention is directed to nanoparticulate compositions comprising nifedipine. The nifedipine particles of the composition have an effective average particle size of less than about 2 microns.Type: ApplicationFiled: November 14, 2003Publication date: June 17, 2004Applicant: Elan Pharma International Ltd.Inventor: Elaine Merisko-Liversidge
-
Publication number: 20040087656Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.Type: ApplicationFiled: October 27, 2003Publication date: May 6, 2004Applicant: Elan Pharma International, Ltd.Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
-
Publication number: 20040057905Abstract: There is disclosed an aerosol comprising droplets of an aqueous dispersion of nanoparticles, said nanoparticles comprising insoluble therapeutic or diagnostic agent particles having a surface modifier on the surface thereof. There is also disclosed a method for making the aerosol and methods for treatment and diagnosis using the aerosol.Type: ApplicationFiled: September 23, 2003Publication date: March 25, 2004Applicant: Elan Pharma International Ltd.Inventors: Ray W. Wood, Lan DeCastro, H. William Bosch
-
Publication number: 20040058009Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.Type: ApplicationFiled: October 27, 2003Publication date: March 25, 2004Applicant: Elan Pharma International, Ltd.Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
-
Publication number: 20040033267Abstract: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.Type: ApplicationFiled: March 20, 2003Publication date: February 19, 2004Applicant: Elan Pharma International Ltd.Inventors: Elaine Merisko-Liversidge, H. William Bosch, Greta A. Cary, John Pruitt, Tuula Ryde, Rajeev Jain, Amy Walters
-
Publication number: 20040033202Abstract: The present invention is directed to nanoparticulate compositions comprising one or more sterols or stanols, such as sitosterol or phytosterol. The sterol particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of sterols and other cholesterol lowering agents are described and methods of using same are taught.Type: ApplicationFiled: June 10, 2003Publication date: February 19, 2004Applicant: Elan Pharma International, Ltd.Inventors: Eugene R. Cooper, Laura Kline, Gary G. Liversidge, Niels P. Ryde
-
Publication number: 20040029099Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.Type: ApplicationFiled: December 20, 2002Publication date: February 12, 2004Applicant: Elan Pharma International Ltd.Inventors: Eugene R. Cooper, John A. Bullock, John R. Chippari, John L. Schaefer, Rakesh A. Patel, Rajeev Jain, Joost Strasters, Niels P. Ryde, Stephen B. Ruddy
-
Publication number: 20040018242Abstract: The present invention is directed to nanoparticulate compositions comprising nystatin. The nystatin particles of the composition have an effective average particle size of less than about 2000 nm.Type: ApplicationFiled: May 5, 2003Publication date: January 29, 2004Applicant: Elan Pharma International Ltd.Inventors: James Cunningham, Elaine Liversidge
-
Publication number: 20040015134Abstract: The present invention relates to a drug delivery device for mixing and delivering a drug by injection. The device includes a housing having a first port or opening therein that receives a first container that contains a fluid or powdered drug, for example a lyophilized drug. The housing can also include a second port or opening that receives a second container that contains a fluid to be mixed with the drug to form an injectable fluid. The device includes a manifold having a channel that fluidly connects the first and second containers. A penetrating membrane such as a needle is used to inject the drug into a patient which is in fluid communication with the first container. The needle is movable from a storage position in the housing to an injection position extending through the housing.Type: ApplicationFiled: July 14, 2003Publication date: January 22, 2004Applicant: Elan Pharma International, Ltd.Inventors: Gilad Lavi, Gil Yigal, Izrail Tsals, Joseph Gross
-
Publication number: 20030232796Abstract: The present invention is directed to nanoparticulate compositions comprising one or more polycosanols. The polycosanol particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of polycosanols and other cholesterol lowering agents are described and methods of using same are taught.Type: ApplicationFiled: June 10, 2003Publication date: December 18, 2003Applicant: Elan Pharma International, Ltd.Inventors: Eugene R. Cooper, Laura Kline, Gary G. Liversidge, Niels P. Ryde
-
Publication number: 20030224058Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.Type: ApplicationFiled: February 21, 2003Publication date: December 4, 2003Applicants: Elan Pharma International, Ltd., Fournier Laboratories Ireland, Ltd.Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins